Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-549	MK2206	1	72	sigmoid	sigmoid	BT549 MK-2206 0 1 72	8	1.811	Inf	0.632	0.189	0.103	0.58	0.8	0.911	0.000695	NA	Inf	0.692	0.839	0.101	0.642	0.73	0.911	0.000717	NA
BT-549	Everolimus	1	72	sigmoid	sigmoid	BT549 everolimus 0 1 72	8	1.772	5.64	0.503	0.444	1e-05	0.367	0.1	0.911	0.000706	NA	437200.0	0.603	0.641	0.000146	0.444	0.1	0.858	0.00286	NA
BT-20	WYE-125132	2	72	sigmoid	sigmoid	BT20 WYE-132 0 2 72	8	2.053	0.012	0.142	0.633	0.00936	0.072	0.621	0.909	0.000752	NA	0.0232	0.316	0.475	0.00613	0.255	0.536	0.894	0.00119	NA
HCC38	AZD-6482	1	72	sigmoid	sigmoid	HCC38 AZD6482 0 1 72	8	1.732	Inf	0.862	0.0239	1.4	0.804	1.03	0.909	0.000761	NA	Inf	0.883	0.98	1.34	0.837	1.03	0.904	0.000873	NA
BT-549	TGX221	2	72	sigmoid	sigmoid	BT549 TGX-221 0 2 72	8	1.927	17.5	0.772	0.0551	123.0	-1.0	0.562	0.907	0.000795	NA	32.3	0.792	0.949	32.3	3.45e-05	0.58	0.899	0.00102	NA
BT-20	AZD-6482	2	72	sigmoid	sigmoid	BT20 AZD6482 0 2 72	8	1.645	0.581	0.0253	0.303	3.86	-1.0	0.58	0.904	0.000884	NA	1.34	0.333	0.772	1.34	0.0	0.582	0.864	0.0025	NA
HCC38	Sirolimus	3	72	sigmoid	sigmoid	HCC38 rapamycin 0 3 72	8	1.420	86.3	0.535	0.403	0.000236	0.361	0.1	0.901	0.000982	NA	75575.0	0.687	0.727	0.000198	0.569	0.1	0.889	0.00136	NA
Hs 578T	MK2206	1		sigmoid	sigmoid	Hs578T MK-2206 1	8	2.039	Inf	0.608	0.165	0.087	0.665	2.09	0.9	0.00101	NA	Inf	0.641	0.845	0.0803	0.689	1.9	0.908	0.000775	NA
BT-549	AS605240	3	72	sigmoid	sigmoid	BT549 AS-605240 0 3 72	8	1.796	Inf	0.863	0.066	4.3	0.721	0.307	0.896	0.00112	NA	Inf	0.881	0.942	4.35	0.756	0.302	0.894	0.00118	NA
Hs 578T	Everolimus	1		sigmoid	sigmoid	Hs578T everolimus 1	8	2.030	1707115.0	0.626	0.318	0.00576	0.429	0.1	0.895	0.00116	NA	2.51e+21	0.657	0.704	0.00121	0.502	0.1	0.893	0.00124	NA
HCC38	CAL-101	2	72	sigmoid	sigmoid	HCC38 idelalisib 0 2 72	8	2.154	Inf	0.881	0.0205	0.901	0.879	3.37	0.892	0.00125	NA	Inf	0.876	0.979	0.891	0.874	3.37	0.887	0.00144	NA
Hs 578T	KIN001-244	2		sigmoid	sigmoid	Hs578T KIN001-244 2	8	2.505	Inf	0.819	0.0357	4.8	0.531	1.14	0.891	0.0013	NA	44.3	0.788	0.957	4.79	0.457	1.1	0.878	0.0018	NA
HCC70	PIK-93	2	72	sigmoid	sigmoid	HCC70 PIK-93 0 2 72	8	1.705	4.34	0.647	0.0132	9.3	-1.0	1.44	0.888	0.0014	NA	6.01	0.718	0.991	6.01	0.0	1.49	0.872	0.00208	NA
BT-20	Alpelisib	3	72	sigmoid	sigmoid	BT20 alpelisib 0 3 72	8	2.541	1.21	0.199	0.21	5.83	-1.0	0.697	0.881	0.00167	NA	1.12	0.272	0.775	1.12	0.0	0.764	0.791	0.00916	NA
HCC1806	Everolimus	3	72	sigmoid	sigmoid	HCC1806 everolimus 0 3 72	8	3.239	Inf	0.813	0.159	0.000271	0.812	0.356	0.879	0.00175	NA	Inf	0.727	0.765	0.00022	0.729	0.377	0.879	0.00177	NA
HCC1806	Everolimus	2	72	sigmoid	sigmoid	HCC1806 everolimus 0 2 72	8	2.871	Inf	0.79	0.178	0.000277	0.79	0.365	0.879	0.00176	NA	Inf	0.727	0.765	0.000222	0.728	0.374	0.879	0.00178	NA
Hs 578T	Sirolimus	1		sigmoid	sigmoid	Hs578T rapamycin 1	8	2.013	110643.0	0.587	0.358	0.000237	0.432	0.1	0.879	0.00178	NA	9.61e+11	0.628	0.672	0.000175	0.487	0.1	0.851	0.00332	NA
BT-549	Sirolimus	1	72	sigmoid	sigmoid	BT549 rapamycin 0 1 72	8	1.817	3.62	0.51	0.438	0.000148	0.318	0.1	0.87	0.00218	NA	506850.0	0.6	0.638	8.82e-05	0.447	0.1	0.8	0.00802	NA
BT-549	TGX221	1	72	sigmoid	sigmoid	BT549 TGX-221 0 1 72	8	1.826	Inf	0.821	0.0771	0.297	0.777	0.632	0.868	0.00232	NA	Inf	0.842	0.931	0.313	0.799	0.603	0.863	0.00255	NA
HCC38	TGX221	3	72	sigmoid	sigmoid	HCC38 TGX-221 0 3 72	8	1.484	3688.0	0.815	0.0743	320.0	0.243	0.273	0.867	0.00233	NA	3261706.0	0.866	0.945	320.0	0.458	0.269	0.867	0.00238	NA
BT-549	CAL-101	3	72	sigmoid	sigmoid	BT549 idelalisib 0 3 72	8	1.770	43.0	0.79	0.0687	320.0	-0.664	0.421	0.862	0.00261	NA	118.0	0.822	0.941	118.0	0.0	0.425	0.854	0.00309	NA
BT-549	AS605240	1	72	sigmoid	sigmoid	BT549 AS-605240 0 1 72	8	1.804	Inf	0.893	0.0436	4.49	0.778	0.375	0.862	0.00261	NA	Inf	0.905	0.961	4.52	0.804	0.371	0.861	0.00267	NA
BT-20	AS605240	1	72	sigmoid	sigmoid	BT20 AS-605240 0 1 72	8	2.142	Inf	0.817	0.0993	3.91	0.634	0.244	0.861	0.00271	NA	Inf	0.814	0.897	3.87	0.629	0.237	0.854	0.00311	NA
HCC1806	Everolimus	1	72	sigmoid	sigmoid	HCC1806 everolimus 0 1 72	8	2.786	Inf	0.784	0.183	0.000282	0.748	0.187	0.86	0.00277	NA	Inf	0.727	0.765	0.00022	0.729	0.377	0.879	0.00177	NA
HCC1806	PIK-93	3	72	sigmoid	sigmoid	HCC1806 PIK-93 0 3 72	8	3.206	56.0	0.873	0.0337	320.0	-0.872	0.579	0.859	0.00279	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)